Investment accounts
Adult accounts
Child accounts
Choosing Fidelity
Choosing Fidelity
Why invest with us Current offers Fees and charges Open an account Transfer investments
Financial advice & support
Fidelity’s Services
Fidelity’s Services
Financial advice Retirement Wealth Management Investor Centre (London) Bereavement
Guides
Guidance and tools
Guidance and tools
Choosing investments Choosing accounts ISA calculator Retirement calculators
Shares
Share dealing
Choose your shares
Tools and information
Tools and information
Share prices and markets Chart and compare shares Stock market news Shareholder perks Stock plan guidance
Pensions & retirement
Pensions, tax & tools
Saving for retirement
Approaching / In retirement
Approaching / In retirement
Speak to a specialist Creating a retirement plan Taking tax-free cash Pension drawdown Annuities Investing in retirement Investment Pathways
Craneware full-year revenue set to top expectations
(Sharecast News) - US healthcare management and support specialist Craneware reported a strong full-year sales performance in an update on Thursday, driven by ongoing investment in the Trisus platform and successful partner programmes, resulting in significant returns for its US healthcare provider customers. The AIM-traded firm said it expected revenue to exceed $188m for the 12 months ended 30 June, surpassing the upper end of current market expectations and marking an 8% increase over the prior year.
It also anticipated delivering an adjusted EBITDA of at least $58m, a 6% increase from 2023's $54.9m, maintaining an above-30% EBITDA margin.
The company said it saw growth in annual recurring revenue (ARR), reaching $172m as of 30 June, up from $169m the previous year.
That growth was expected to continue as more sales and partner successes converted to ARR.
Craneware said its strong cash generation enabled continued investment in its future while also significantly reducing its total bank debt to $35.4m, a $40m reduction beyond normal scheduled repayments from 2023's $83m.
It said it returned $12.8m to shareholders through dividends, up from $12.1m in the 2023 financial year, and completed $3.3m in share purchases via its share buyback programme and the employee benefit trust.
Additionally, Craneware said it retained healthy cash reserves of $34.6m as of 30 June, down from $78.5m a year earlier.
Looking ahead, the firm said its strong sales performance underscored the robustness of its Trisus platform, increasing partner success, and its unique market position.
The company said its range of solutions and new market opportunities, accelerated innovation, and exploration of AI-based applications - bolstered by a recently-announced alliance with Microsoft - positioned it to provide valuable insights to its customers.
"The drive for better value in healthcare continues to dominate strategic priorities within the US healthcare market," said chief executive officer Keith Neilson.
"Our positive financial results reflect the demonstrable impact the Craneware Group can make, in helping our customers meet these priorities.
"The exciting growth and expansion opportunities that our new alliance with Microsoft brings to the group, combined with our continued investment in the Trisus platform, the considerable data assets we maintain, and our independence within the US healthcare market mean we are uniquely placed to support all US hospitals."
Craneware said it would announce its results for the year ended 30 June on 3 September.
At 1330 BST, shares in Craneware were up 1.41% at 2,444p.
Reporting by Josh White for Sharecast.com.
Share this article
Related Sharecast Articles
Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.
Award-winning online share dealing
Search, compare and select from thousands of shares.
Expert insights into investing your money
Our team of experts explore the world of share dealing.
Policies and important information
Accessibility | Conflicts of interest statement | Consumer Duty Target Market | Consumer Duty Value Assessment Statement | Cookie policy | Diversity, Equity & Inclusion | Diversity, Equity & Inclusion Reports | Doing Business with Fidelity | Investing in Fidelity funds | Legal information | Modern slavery | Mutual respect policy | Privacy statement | Remuneration policy | Staying secure | Statutory and Regulatory disclosures | Whistleblowing programme
Please remember that past performance is not necessarily a guide to future performance, the performance of investments is not guaranteed, and the value of your investments can go down as well as up, so you may get back less than you invest. When investments have particular tax features, these will depend on your personal circumstances and tax rules may change in the future. This website does not contain any personal recommendations for a particular course of action, service or product. You should regularly review your investment objectives and choices and, if you are unsure whether an investment is suitable for you, you should contact an authorised financial adviser. Before opening an account, please read the ‘Doing Business with Fidelity’ document which incorporates our client terms. Prior to investing into a fund, please read the relevant key information document which contains important information about the fund.
This website is issued by Financial Administration Services Limited, which is authorised and regulated by the Financial Conduct Authority (FCA) (FCA Register number 122169) and registered in England and Wales under company number 1629709 whose registered address is Beech Gate, Millfield Lane, Lower Kingswood, Tadworth, Surrey, KT20 6RP.